Disparities in Utilization and Adherence to Antiamyloid Therapies in Alzheimer’s Disease and Mild Cognitive Impairment
This study reveals that younger, non-Hispanic White patients with fewer comorbidities and lower socioeconomic vulnerability are more likely to receive antiamyloid medications for Alzheimer’s, while higher comorbidity predicts lower initial adherence.